Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we talk about how startups are looking for new ways to price drugs, particularly GLP-1s, see how tracking circulating tumor DNA holds promise in cancer treatment, and more.
The need-to-know this morning
- Alkermes announced the acquisition of Avadel Pharmaceuticals, maker of an approved sleep medicine, in a transaction valued at up to $2.1 billion.
- Arcturus Therapeutics reported interim results from a mid-stage study of an mRNA-based treatment for cystic fibrosis that showed no improvement in lung function over 28 days.
- Summit Therapeutics raised $500 million in a private placement, more than half of which is being bought by company insiders, including co-CEO Robert Duggan.
Startups pitch new ways to cover costly drugs
As pharma giants and President Trump push direct-to-consumer drug sales, startups are pitching employers on a new model to subsidize cash prices for branded medications such as Wegovy and Zepbound — bypassing insurance altogether.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply